What is the typical dosage and usage of Moclobemide (Zorix) for treating depression and social anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Moclobemide (Zorix) Dosage and Usage for Depression and Social Anxiety

For depression, moclobemide should be started at 300 mg/day divided into 2-3 doses, with a typical therapeutic range of 300-600 mg/day. For social anxiety disorder, higher doses of 600-900 mg/day are often required for optimal efficacy. 1, 2

Dosage Guidelines

For Depression:

  • Initial dose: 300 mg/day divided into 2-3 doses
  • Typical therapeutic range: 300-600 mg/day
  • Maximum dose: 600 mg/day
  • Administration: Take with food to improve tolerability

For Social Anxiety Disorder:

  • Initial dose: 300 mg/day divided into 2-3 doses
  • Therapeutic range: 600-900 mg/day (higher doses tend to be more effective)
  • Maximum dose: 900 mg/day
  • Duration: Long-term treatment may be necessary as studies show high relapse rates (88%) after discontinuation 3, 4

Pharmacokinetics

  • Reaches steady-state plasma levels after approximately one week
  • After multiple dosing, oral bioavailability approaches 100%
  • Short plasma elimination half-life allows switching to alternative agents within 24 hours if needed 2

Monitoring and Titration

  • Plasma concentration monitoring is useful in determining optimal dosing
  • Target plasma concentration: 216±55 ng/mL at 100 mg three times daily 1
  • Titrate dose gradually to minimize side effects
  • Assess response after 2-4 weeks at a stable dose

Special Populations

Elderly:

  • Particularly suitable for elderly patients due to minimal cognitive, psychomotor, and cardiovascular effects 2
  • Start at lower doses and titrate more slowly

Renal Impairment:

  • No dose adjustment required in renal dysfunction 2

Hepatic Impairment:

  • Dose reduction necessary in severe hepatic impairment 2

Side Effects and Management

Common Side Effects:

  • Insomnia (11.2%)
  • Dizziness (4.5%)
  • Dry mouth (3.7%)
  • Nausea
  • Headache 5

Management of Side Effects:

  • Take with food to reduce gastrointestinal effects
  • Divide daily dose to minimize insomnia
  • Most side effects are mild and occur mainly in the first 2 months of treatment 3

Drug Interactions and Precautions

Major Precautions:

  • Avoid combining with other serotonergic medications due to risk of serotonin syndrome 1
  • Do not combine with MAOIs including other MAOIs, phenelzine, isocarboxazid, isoniazid, and linezolid 1
  • Exercise caution when combining with:
    • SSRIs or SNRIs
    • Opioids (especially pethidine, dextropropoxyphene)
    • Tricyclic antidepressants
    • Stimulants 1, 2

Dietary Considerations:

  • Unlike irreversible MAOIs, strict dietary restrictions are not required at standard doses
  • However, at doses above 900 mg/day, tyramine-rich food interactions may become clinically relevant 2

Efficacy Considerations

  • Moclobemide is as effective as tricyclic antidepressants and SSRIs for depression 2
  • For social anxiety, higher doses (600-900 mg/day) tend to show better efficacy 6, 4
  • Long-term treatment may be necessary, particularly for social anxiety disorder, as studies show high relapse rates after discontinuation 3, 4

Treatment Duration

  • For depression: Minimum 6 months after symptom resolution
  • For social anxiety: Long-term treatment often required, with studies showing benefit from continuous treatment for up to 2 years 3, 4

Discontinuation

  • Taper gradually to minimize discontinuation symptoms
  • Monitor closely for relapse, especially in social anxiety disorder where relapse rates of 88% have been observed after discontinuation 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The long-term treatment of social phobia with moclobemide.

International clinical psychopharmacology, 1996

Research

Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.

International clinical psychopharmacology, 1997

Research

Moclobemide in social phobia: a controlled dose-response trial.

Journal of clinical psychopharmacology, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.